54: Survival Analysis of Tumor Incidence in a Randomized Placebo-Controlled Clinical Trial

Music City Center 

Clonal hematopoiesis (CH), a condition increasingly prevalent with aging, has been associated with elevated risks of hematological malignancies and cardiovascular diseases. The most frequent CH-associated mutations occur in the DNMT3A and TET2 genes, leading to heightened proinflammatory signaling. We conducted a stratified analysis to evaluate the incidence of non-hematological malignancies by treatment group and CH mutation status. The Kaplan-Meier and risks models are used to compare malignancy outcomes over the trial period. The incidence of non-hematological malignancies across cancer subtypes are assessed for patients with TET2 or DNMT3A mutations. Those individuals from experimental arm exhibited distinct performance on various cancer types. The estimated cumulative incidence of at least one malignancy event was also assessed to understand the outcomes for the individuals with TET2-mutant and treated with treatment compared to the placebo group. The observed reduction in cancer incidence among TET2-mutant highlights a potential role for anti-inflammatory in cancer prevention and warrants further investigation using causal inference and longitudinal modeling approaches.

Kaplan-Meier

longitudinal modeling

malignancies 

Section on Statistics in Genomics and Genetics